Long noncoding RNA LINP1 promoted proliferation and invasion of ovarian cancer via inhibiting KLF6
Authors: Y-L Dong
H Xu
L Zhu
C-Z Hou
Y Li
Journal: European Review for Medical and Pharmacological Sciences (2020)
Discipline: PHARMACOLOGY & TOXICOLOGY
Keywords: Ovarian cancer; long noncoding ribonucleic acids (lncRNAs); LINP1; tumor progression; quantitative real-time polymerase chain reaction (qRT-PCR)
Affiliations: Department of Obstetrics and Gynecology, The Second Hospital of Shandong University, Jinan, Shandong, China. .

Abstract:  Objective: Ovarian cancer is one of the most ordinary fatal cancers. The role of long noncoding ribonucleic acids (lncRNAs) in tumor progression has caught the attention of numerous researchers. In this work, lncRNA LINP1 was studied to identify how it functioned in the progression of ovarian cancer. Patients and methods: Firstly, quantitative real-time polymerase chain reaction (qRT-PCR) was utilized to measure LINP1 expression in ovarian cancer tissues. Furthermore, to identify the function of LINP1 in ovarian cancer, functional experiments were conducted. Also, by performing qRT-PCR and Western blot assay, the underlying mechanism was explored. Results: In this research, LINP1 expression was remarkably higher in ovarian carcinoma samples compared with adjacent tissues. Moreover, cell proliferation, migration, and invasion were inhibited after LINP1 was silenced in the ovarian cancer cells. Besides, the messenger (mRNA) and the protein of KLF6 were overexpressed after LINP1 was silenced. Furthermore, the KLF6 expression level was negatively related to the LINP1 expression level in ovarian cancer samples. Conclusions: We discovered a potential oncogene in ovarian cancer and identified that LINP1 enhanced cell metastasis and proliferation via down-regulating KLF6. 

Retracted: Yes

PubPeer comments:
 This paper is one of a set of 121 papers that all contain images from the same library of about 100 photos and plots. This is unexpected, because each paper has different authors and different affiliations, with little to no overlap, and describes different cancer types and molecules. It would be very hard to explain how authors from different labs would all obtain the same photo. Therefore, the papers might have all be derived from the same source, such as a paper mill that sells ready-to-be-published papers. This  Stock Photo paper set has been described in more detail on my blog post, https: scienceintegritydigest.com 2020 07 05 the-stock-photo-paper-mill and in a Wall Street Journal article by Eva Xiao (currently behind a paywall): https: www.wsj.com articles chinese-research-papers-raise-doubts-fueling-global-questions-about-scientific-integrity-11593939600 The vast majority (113 121) of the papers were published in the same journal, European Review for Medical and Pharmacological Sciences (ERMPS). A link to the full set of papers can be found here: https: docs.google.com spreadsheets d 172RWS18w1lTNJ9Nnj80fuXXTqTm4fGkoK0sdYyvKE3g edit?usp=sharing All papers have been reported to the journal editors on July 2, 2020. , 
 Article has been withdrawn. The retraction notice is not linked to the article, but can be found here: https: www.europeanreview.org article 22452 It reads:  *Since this article has been suspected of research misconduct and the corresponding authors did not respond to our request to prove originality of data and figures, u201cLong noncoding RNA LINP1 promoted proliferation and invasion of ovarian cancer via inhibiting KLF6, by Y. Li, C.-Z. Hou, Y.-L. Dong, L. Zhu, H. Xu, published in Eur Rev Med Pharmacol Sci 2020; 24 (1): 36-42u2013DOI: 10.26355 eurrev_202001_19893u2013PMID: 31957816u201d has been withdrawn.* *The Publisher apologizes for any inconvenience this may cause.* , 
 Via http: www.most.gov.cn zxgz kycxjs kycxgzdt 202203 t20220318_179892.html u3000u30006. The paper  Long noncoding RNA LINP1 promoted proliferation and invasion of ovarian cancer via inhibiting KLF6 from the Second Hospital of Shandong University with Xu Hui as the corresponding author and Li Yue as the first author. After investigation, it was found that there were acts of buying and selling papers and improper signatures in the paper. Xu Hui was unaware of the process of writing, submitting and publishing the paper; he dealt with Li Yue as follows: a serious warning from the party, lowering the post level, from the 11th-level physician position to the 12th-level physician post, canceling the qualification for promotion to professional and technical positions3 Years, the qualification for applying for scientific and technological plans (special projects, funds, etc.) will be cancelled for 5 years. ,